Therapeutic cancer vaccines have experienced a remarkable resurgence over the past decade, representing a paradigm shift in ...

If you live in the United States, odds are high that a tiny passenger rides in your blood. By adulthood, more than 94 percent ...

Q3 2025 Earnings Call November 13, 2025 4:30 PM ESTCompany ParticipantsDavid Dodd - Chairman, President & CEOMark Reynolds ...

The Donor Selection & Cell Source Summit, hosted by Hanson Wade, brings together leaders from industry and academia to address critical bottlenecks in donor screening, cell sourcing, and process ...

MiNK-215, an IL-15 armoured FAP-targeting CAR-iNKT, targets and clears tumor-protective FAP+ fibroblasts to allow immune cells to infiltrate and ...

The field of tissue-immune interactions has undergone significant transformation as emerging evidence demonstrates the centrality of local microenvironments ...

Cancer immunology research has increasingly focused on the complex interactions between oncogenic drivers, such as KRAS mutations, and the tumor ...

During a live event, Thomas G. Martin, MD, discussed updated findings from the CARTITUDE-1 trial of cilta-cel and what they signify for patients with no disease progression at 5 years.

"Solid tumors are often difficult to treat because the immune system within the tumor gets switched off," said Michelle H. Nelson, PhD, Director of Immunobiology at Aptevo. "APVO451 is designed to ...

Artificial intelligence (AI) is set to transform the care of women with cancer. From early detection via digital phenotyping ...

Study shows aging tissues resist tumors even as mutations accumulate. Reveals why cancer rates decline after 85 and opens treatment paths.